Semaglutide for Older Adults: 5 Things We Wish We'd Known

For years, if you were 65 or older and your doctor mentioned semaglutide, there was an uncomfortable gap in the conversation. The drug worked — that much was clear. But the original STEP trials that made semaglutide famous had enrolled relatively few older adults, so clinicians were essentially making educated guesses about how the medication behaved in people our age. That gap just got a lot smaller. A pooled analysis of six STEP clinical trials, presented at the 33rd European Congress on Obesity (ECO2026) in May 2026 by Prof. Luca Busetto of the University of Padova, focused specifically on 358 adults aged 65 and older without diabetes. The findings on semaglutide for older adults are both reassuring and, in a couple of places, genuinely surprising. Here are five things we wish we'd known sooner.

1. The Weight Loss Is Real — and It Holds Up at 65+

What most people get wrong is assuming that metabolism slows so dramatically after 65 that weight-loss medications simply won't deliver the same results. The ECO2026 pooled analysis says otherwise. Older adults in the six STEP trials lost substantial body weight on semaglutide — comparable in magnitude to what was seen in younger participants. That's not a minor footnote. It's the kind of confirmation that changes clinical conversations.

To put it in broader context: a prespecified analysis of the SELECT trial, which enrolled 17,604 adults aged 45 and older, found semaglutide produced sustained weight loss of −10.2% and reduced waist circumference by −7.7 cm over four years. Crucially, those benefits held across all sexes, races, and body sizes. The ECO2026 data now extends that confidence specifically into the 65+ bracket — a group that, until recently, had been largely left out of the evidence base.

Why does waist circumference matter so much? Because abdominal fat in older adults is directly tied to metabolic risk, mobility limitations, and cardiovascular strain. Losing inches around the middle isn't just about how clothes fit. It's about what's happening inside.

2. The Heart Benefits May Matter Even More Than the Weight Loss

Here's the counterintuitive point we really wish someone had made earlier: for older adults, the cardiovascular improvements from semaglutide might actually be more clinically significant than the number on the scale.

The ECO2026 analysis found meaningful cardiometabolic improvements in adults 65+ — including changes in blood pressure, cholesterol markers, and other cardiovascular risk factors. This aligns with what the landmark SELECT trial demonstrated: semaglutide reduced major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% over roughly 40 months in adults with obesity and preexisting cardiovascular disease. No diabetes required.

Think about that for a moment. A 20% reduction in serious cardiac events. For someone in their late 60s or 70s managing hypertension and carrying extra weight, that number has real weight to it. The medication isn't just reshaping bodies — it's reshaping risk profiles.

The cardiometabolic improvements seen in the pooled STEP data for older adults follow the same pattern. Blood pressure improvements. Better lipid markers. Less systemic inflammation. These aren't side benefits. For our age group, they may be the main event.

3. "Underrepresented" Is a Polite Word for a Real Problem

We should be honest about what the phrase "underrepresented in clinical trials" actually means in practice. It means that for several years, prescribing semaglutide to someone over 65 involved extrapolating from data gathered mostly on younger people. Doctors were doing their best with incomplete information. Patients were making decisions without the full picture.

Prof. Busetto's pooled analysis — drawing on 358 older adults across six trials — is specifically designed to close that gap. It's not a massive sample by trial standards, but it's the most targeted and rigorous look we've had at this population. And the signal is consistent: semaglutide works, the benefits are real, and the risk profile in older adults without diabetes appears manageable.

The WHO took a related step in December 2025, issuing its first-ever pharmacological guideline on GLP-1 therapies for obesity, with conditional recommendations supporting long-term use of semaglutide in adults living with obesity — combined with healthy diet, physical activity, and person-centered care. The phrase "person-centered" matters here. It's an acknowledgment that older adults aren't a monolith. Age alone doesn't determine whether someone is a good candidate.

4. Muscle Loss Is the Conversation You Need to Have First

This is where we'd push back gently on the enthusiasm, because there's a real nuance that gets lost in the excitement over weight-loss numbers. When older adults lose weight — through any method — a portion of that loss is often lean muscle mass. And after 65, muscle mass is something we genuinely can't afford to lose carelessly. It affects balance, fall risk, functional independence, and metabolic health.

What most people get wrong is treating semaglutide as a standalone solution. The ECO2026 findings, and the WHO guideline, are both clear that medication works best alongside physical activity and nutritional support. For older adults specifically, that means resistance training — not just walking — and adequate protein intake. These aren't optional add-ons. They're how you protect the muscle while losing the fat.

Before starting semaglutide, the conversation with your doctor should include: How will we monitor muscle mass? What's the plan for physical activity? Are there any concerns about my current protein intake? These questions aren't pessimistic — they're how you make the treatment work properly.

5. Cognitive Load and Stress Can Quietly Undermine Any Treatment Plan

This one doesn't show up in the clinical trial data, but it's real. Managing a new medication — especially one with a titration schedule, potential GI side effects in the early weeks, and regular monitoring appointments — takes mental bandwidth. For older adults juggling multiple health conditions, that cognitive load adds up.

We've seen this pattern repeatedly: people start a promising treatment, the logistics pile up, stress increases, sleep suffers, and adherence quietly erodes. Keeping your brain engaged and your stress levels manageable isn't a luxury — it's part of the treatment infrastructure.

That's part of why we built SteadiDay's Mind Breaks feature — free short brain games designed specifically for adults 50+. They're not about becoming a puzzle champion. They're about giving your mind a genuine rest from the noise of managing health decisions, so you can show up more clearly for the things that matter. A calmer, more focused mind makes better health choices. It's that straightforward.

What This All Means for Your Next Doctor's Appointment

The ECO2026 pooled analysis doesn't mean semaglutide is right for every older adult. It means clinicians finally have real data to bring to the conversation — and so do we. If you've been curious about whether GLP-1 medications are appropriate for someone your age, you're no longer asking a question that science can't answer. The evidence now exists specifically for adults 65 and older without diabetes.

Come to your appointment with specifics. Ask about the cardiovascular benefits relative to your personal risk profile. Ask about muscle preservation strategies. Ask how long treatment is typically maintained and what monitoring looks like. The ECO2026 findings, the SELECT trial data, and the WHO's 2025 guideline all point in the same direction: this is a legitimate option for older adults, best used as part of a genuinely coordinated care plan — not a prescription handed over and forgotten.

The data is finally here. Now it's about asking the right questions with it.

Common Questions

Is semaglutide safe for adults over 65 who don't have diabetes?

Based on a pooled analysis of six STEP clinical trials presented at ECO2026, semaglutide produced substantial weight loss and cardiometabolic improvements in adults aged 65 and older without diabetes, with a manageable risk profile. As with any medication, individual health history matters — your doctor should review your full picture, including kidney function, other medications, and cardiovascular status, before starting treatment.

How much weight can an older adult realistically expect to lose on semaglutide?

The ECO2026 pooled data showed meaningful weight loss in the 65+ group comparable to younger participants in the STEP trials. Broader trial data from the SELECT study found an average sustained weight loss of around 10% of body weight over four years in adults 45 and older. Individual results vary depending on dose, lifestyle factors, and how long treatment continues.

Does semaglutide cause muscle loss in older adults, and how can that be prevented?

Weight loss from any cause — including semaglutide — can involve some loss of lean muscle mass, which is a genuine concern for older adults. The best evidence supports combining semaglutide with resistance exercise and adequate dietary protein to protect muscle while losing fat. Discuss a specific muscle-preservation plan with your doctor or a registered dietitian before starting treatment.

How does semaglutide help the heart, and does that apply to people over 65?

The SELECT trial found semaglutide reduced major cardiovascular events — including heart attack, stroke, and cardiovascular death — by 20% in adults with obesity and preexisting heart disease. The ECO2026 analysis found similar cardiometabolic improvements in adults 65 and older, suggesting the heart benefits extend meaningfully into older age groups. These benefits occur partly through weight loss and partly through direct effects on blood pressure, inflammation, and lipid levels.